InDex Pharmaceuticals gets patent for additional DIMS compounds granted in the US
March 14, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company’s DIMS platform has been granted by the United States Patent and Trademark Office (USPTO).InDex has a discovery stage portfolio of more than 150 DNA-based ImmunoModulatory Sequences (DIMS), several of which are already protected by approved composition-of-matter patents. The new US patent, entitled Methods for identifying biologically active oligonucleotides capable of modulating the immune system (patent number 9593337), covers both the composition-of-matter and